

**20-22 SETTEMBRE 2023**

**BARI | VILLA ROMANAZZI CARDUCCI**

**7° Forum  
Mediterraneo  
2023 in Sanità®**



**Innovazione In Sala Operatoria : La  
Chirurgia Robotica in Chirurgia  
Generale**

Maurizio Brausi  
Presidente Collegio Italiano Chirurghi (CIC)  
Direttore Scientifico CUrE  
Hesperia Hospital  
Modena



**Collegio Italiano  
dei Chirurghi**

**20-22 SETTEMBRE 2023**

**BARI | VILLA ROMANAZZI CARDUCCI**

**7° Forum  
Mediterraneo  
2023 in Sanità®**



## **Collegio Italiano dei Chirurghi**

Comprende 59 Società Chirurgiche Italiane che fanno capo a circa 50.000 chirurghi




## Storia della Chirurgia Robotica

- Il termine Robot e Robotica e' stato introdotto negli anni 20 da Capek (Cecoslovacco)
- La Robotica in chirurgia è nata in USA nel 1985 come PUMA 560 usata per biopsie cerebrali di alta precisione
- All'inizio degli anni 90 l'esercito americano stabilì una collaborazione con l'Istituto di ricerca di STANFORD: obiettivo...TELECHIRURGIA per operare da lontano ed in tempi veloci i feriti sul campo di battaglia e diminuire la mortalità. Ospedali chirurgici mobili collegati a distanza con un operatore








## Current





### Why Robotic RP ... Benefits?

- Smaller incisi 
- Less pain 
- Better Vision 
- Intuitive..easy movements 
- Less blood loss
- **Faster Recovery**
- **Short Learning curve for young** 5






## Numero interventi dal 2021 al dicembre 2022 in Italia


- Sono stati eseguiti più di 35.000 interventi con un aumento del 16% rispetto al 2021
- Specialità
  1. Urologia (67%)
  2. Chirurgia Generale (16%)
  3. Ginecologia (10%)
  4. Chir. Toracica
  5. Otorino



2022 : 37.000 new cases of PCA  
Number of RARPs in the US



Red: open  
Green: robotic  
Blue: total



Alemozaffar et al, Eur Urol 2015 67-432-438  
Lowrance et al, J Urol 2012 187:2087-2093



**20-22 SETTEMBRE 2023**


**BARI | VILLA ROMANAZZI CARDUCCI**

**7° Forum  
Mediterraneo  
2023 in Sanità®**

## Domande

- Costo-beneficio
- Sostenibilità
- Futuro.... teaching

**Surgical Process**





**20-22 SETTEMBRE 2023**

**BARI | VILLA ROMANAZZI CARDUCCI**


**7° Forum  
Mediterraneo  
2023 in Sanità®**

## Innovazione in Sala Operatoria: La Chirurgia Robotica




Maurizio Brausi  
Presidente CIC  
Scientific Director **C.Ur.E**  
Dept of Urology  
Hesperia Hospital Institute Modena  
*e-mail: maurziobrausi@gmail.com*

2022 : 37.000 new cases of PCA  
Number of RARPs in the US



Red: open  
Green: robotic  
Blue: total





**20-22 SETTEMBRE 2023**

**BARI | VILLA ROMANAZZI CARDUCCI**


**7° Forum  
Mediterraneo  
2023 in Sanità®**

## Advent of Robotic surgical technology

- Initially developed by the US Department of Defense for use in military battlefield applications, robotic technology was adapted for civilian use through the efforts of 2 rival corporations, **Intuitive Surgical**, and **Computer Motion**
- These companies simultaneously developed robotic interfaces for use in human surgical applications.
- Computer Motion, Inc, introduced the Zeus Surgical System at approximately the same time that Intuitive Surgical, Inc, developed its **da Vinci Surgical System**.







## Why Robotic RP .... Benefits?


- Smaller incision
- Less pain
- Better Vision
- Intuitive..easy movements
- Less blood loss
- *Faster Recovery*
- *Short Learning curve for young*



16



### Surgical Process





## *The Da Vinci System*




ENDOWRIST.

- The first reported robot-assisted laparoscopic prostatectomy using the da Vinci system was described by Abbou et al in 2001.<sup>[4]</sup>
-



## Current



**20-22 SETTEMBRE 2023**

**BARI | VILLA ROMANAZZI CARDUCCI**

**7° Forum  
Mediterraneo  
2023 in Sanità®**

### **Advent of Robotic surgical technology**


- Initially developed by the US Department of Defense for use in military battlefield applications, robotic technology was adapted for civilian use through the efforts of 2 rival corporations, **Intuitive Surgical**, and **Computer Motion**
- These companies simultaneously developed robotic interfaces for use in human surgical applications.
- Computer Motion, Inc, introduced the Zeus Surgical System at approximately the same time that Intuitive Surgical, Inc, developed its **da Vinci Surgical System**.






## Rise of robotic radical prostatectomy

- Menon et al from the Vattikuti Urology Institute at Henry Ford Hospital in Detroit, Michigan, are responsible for the development and popularization of robotic radical prostatectomy<sup>1</sup>
- Presently the transperitoneal approach is the most widely adopted because of the quick and easy access to the peritoneal cavity
- This technique has been gaining widespread acceptance in the US and Europe and is increasing in penetration worldwide.



## Outline

- Surgical Quality
- Morbidity and Mortality
- Oncologic Outcomes



22



**20-22 SETTEMBRE 2023**

**BARI | VILLA ROMANAZZI CARDUCCI**

**7° Forum  
Mediterraneo  
2023 in Sanità®**

## **SURGICAL QUALITY**

23

## **Technique for Robotic RP**

- The basic technique for performing minimally invasive RP is the same regardless of the technology used.
- Personal attitude: with robot I try to reproduce the same technique I use in Open RP: our center of Modena-Carpi performed > 3500 cases of ORP
- **Main steps :**
  1. e-LND (intermediate-high-risk pts)
  2. Bladder neck preservation when possible
  3. Nerve sparing if indicated (accurate)
  4. Urethral Length Preservation (veru montanum seen)
  5. Water tight urethro-vesical anastomosis (Van Velthoven T.)



**20-22 SETTEMBRE 2023**

**BARI | VILLA ROMANAZZI CARDUCCI**

**7° Forum  
Mediterraneo  
2023 in Sanità®**


## VARIABILITY AMONG SURGEON'S ON CANCER CONTROL AFTER RADICAL PROSTATECTOMY

**Bianco FJ.**<sup>1AD</sup>, Vickers A.<sup>12A</sup>, Serio A.<sup>12A</sup>, Eastham JA.<sup>1A</sup>,  
Kline EA.<sup>1A</sup>, Reuther A.<sup>1B</sup>, Kattan MW.<sup>3B</sup>, Pontes JE.<sup>1C</sup>, **Scardino PT.**<sup>1A</sup>

Departments of Urology<sup>1</sup>, Biostatistics<sup>2</sup> and Quantitative Health Sciences<sup>3</sup>  
Memorial Sloan-Kettering Cancer Center.<sup>A</sup>  
Cleveland Clinic Foundation.<sup>B</sup>  
Wayne State University.<sup>C</sup>  
George Washington University.<sup>D</sup>

### 5-YR BCR-FREE PROBABILITIES BY SURGEON EXPERIENCE

*Vickers & Bianco et al. JNCI (2008)*






## VARIATION AMONG SURGEONS

- Significant heterogeneity in BCR rates was observed between surgeons ( $p < 0.01$ )
- $I^2 = 0.38$ , implies that 38% of the observed difference in BCR rates between surgeons can be explained by genuine differences in surgical technique and approach, rather than by chance alone


## Learning Curve?



- In order to be able to perform a good robotic RP 50-70 cases needed vs 500 for open RP (Brausi Eur Urol 2017)

28







**20-22 SETTEMBRE 2023**

**BARI | VILLA ROMANAZZI CARDUCCI**

**7° Forum  
Mediterraneo  
2023 in Sanità®**

## ONCOLOGIC OUTCOMES

30



## Positive Surgical Margins

Study	Type	N	RRP	RARP	P Value
Yaxley et al '16	Randomized by surgeon A vs B	326	10%	15%	0.21
Desai et al '18	VA Database	244	41%	32%	0.18
Ong et al '15	Registry Victoria Australia	2002	34%	23%	<0.001
Alemozaffar et al '14	Health Professionals Follow Up Study	903	23%	24%	0.51
Haglund et al '15	Prospective non-randomized cohort (LAPPRO)	2431	21%	22%	NS
Guazzoni et al '06	Randomized, one surgeon	120	22%	26%	0.28

## Oncological Outcomes after RARP

- *Oncological Outcomes after RARP: long term F-up in 4803 patients .*  
**Results:** RARP confers effective long-term Biochemical Control  
(Sukumar S et al BJUI 2014)
- *Long term control outcomes of RARP for PCA treatment a Metanalysis*  
20 Studies from 2010 to 1016 included.  
**Results:** No significant difference in 5-10 CR-free and CSS when  
compared to ORP (Wang L et al Int Urol Nephrol 2017)
- *Oncological Outcomes after RARP: a large european Single-Center Cohort  
with median 10 Yr F-up*  
885 patients . **Results:** RARP is effective after 10 years  
(Rayan P et al Eur Urol Focus 2018)



## Oncological Outcomes After RARP

- RARP has similar oncological outcomes to open RP but improved potency outcomes....  
(Bath KRS et al J Endourol 2021)
- *The RECUORSE Study: long term o associated oncological outcomes associated with RARP : cervical, colorectal, lung and PCA: a systematic review and metanalysis*  
157,876 Robotic cases 68,007 Laparoscopic/thoracoscopic cases and 234,649 Open cases  
**Results:** For PCA long term outcomes similar for Robotic vs VDL vs Open surgery  
(Leitao MM et al Ann Surg 2023)

**20-22 SETTEMBRE 2023**

**BARI | VILLA ROMANAZZI CARDUCCI**

**7° Forum  
Mediterraneo  
2023 in Sanità®**

## MORBIDITY AND MORTALITY

34



## Estimated Blood Loss

Study	Type	N	RRP	RARP	P Value
Yaxley et al '16	Randomized by surgeon A vs B	326	1338	443	<0.001
Desai et al '18	VA Database	244	1075	200	<0.001
Alemozaffar et al '14	Health Professionals Follow Up Study	903	852	207	<0.001
Haglind et al '15	Prospective non-randomized cohort (LAPPRO)	2431	550	100	<0.001
Guazzoni et al '06	Randomized, one surgeon	120	853	257	<0.001

35

## Transfusion Requirement

Study	Type	N	RRP	RARP	P Value
Yaxley et al '16	Randomized by surgeon A vs B	326	4%	1%	0.12
Desai et al '18	VA Database	244	44%	1%	<0.001
Alemozaffar et al '14	Health Professionals Follow Up Study	903	30%	4%	<0.001
Forsmark et al '18	Prospective non-randomized cohort (LAPPRO)	2431	0.58	0.19	<0.001
Guazzoni et al '06	Randomized, one surgeon	120	54%	13%	<0.001

36



## Complications

Study	Type	N	RRP	RARP	P Value
Yaxley et al '16	Randomized by surgeon A vs B	326	9%	4%	0.05
Desai et al '18	VA Database	244	37%	6%	<0.001
Guazzoni et al '06	Randomized, one surgeon	120	13%	10%	0.01

37

## Length of Stay


Study	Type	N	RRP	RARP	P Value
Yaxley et al '16	Randomized by surgeon A vs B	326	3.3	1.6	<0.001
Desai et al '18	VA Database	244	3	2	<0.001
Alemezaffar et al '14	Health Professionals Follow Up Study	903	2.9	1.8	<0.001
Haglind et al '15	Prospective non-randomized cohort (LAPPRO)	2431	4	3	<0.001



### Operating Room Time (min)


Study	Type	N	RRP	RARP	P Value
Yaxley et al '16	Randomized surgeon A vs B	326	280	246	<0.001
Desai et al '18	VA Database	244	325	390	<0.001
Haglund et al '15	Prospective non-randomized cohort (LAPPRO)	2431	126	236	<0.001
Guazzoni et al '06	Randomized, one surgeon	120	170	235	<0.001

## Recurrence Free Survival





## Recurrence Free Survival



### Outcomes of **Functional Parameters** with RARP

Series	Number of Patients	Positive Margin	Definition of Potency	Patients Achieving Potency	Definition of Continence	Patients Achieving Continence
Badani et al (2007) <sup>[11]</sup>	2766	12.0	Intercourse	79.2% at 12 mo	≤1 pad per day	93% at 12 mo
Ahlering et al (2004) <sup>[43]</sup>	140	12.3% (pT2)	Not reported	Not reported	No pads	76% at 3 mo
		48.8% (pT3)				
Patel et al (2003)	200	5.7% (pT2)	Not reported	Not reported	No pads	98% at 6 mo
		26.3% (pT3)				
Joseph et al (2003)	325	9.9% (pT2)	IIEF >21	68% at 6 mo	No pads	96% at 6 mo
		32.7% (pT3a)				



## Yaxley et al 2016

	Baseline RRP	Baseline RALP	P Value	12 week RRP	12 week RALP	P Value
EPIC-Urinary Domain	88.8	88.5	0.83	83.8	82.5	0.48
EPIC-Sexual Domain	59.8	63.1	0.25	35.0	38.9	0.18
EPIC-Overall QOL	44.0	46.7	0.30	27.6	30.1	0.31

***RARP vs Lap and Open RP:  
Functional outcomes 18 mos after diagnosis: a national  
Cohort study in UK (Nossiter et al BJC 2018)***

- **Method:** all men diagnosed with Pca in England during April-October 2014 who received RP identified by the National PCA audit and mailed a questionnaire 18 months after diagnosis are part of this study. Functional domains were requested using Epic-26 domain scores, generic health QoL (HR QoL); EQ-5D-5L scores were estimated
- **Results :** 2219 men (77%) responded:  
1310 (59%) RARP  
487 (21.9%) LRP  
422 (19%) ORP.  
***NO DIFFERENCE in all domains... a trend in higher sexual function scores for RARP***



## Indications for Robotic Radical Prostatectomy: 2022 eau Guidelines



- Patients at **intermediate PCA and life expectancy > 10 years**: perform LND if the estimate risk for positive LNs exceeds 5% (SR: Strong)
- Patients with **high risk localised Pca** and a life expectancy of > 10 years only as part of multi-modal therapy (SR: Strong).. Perform an e-PLND in these patients (SR Strong)  
Do not perform a frozen section of nodes during RP to decide whether to proceed with or abandon the procedure (SR: Strong)
- **Locally Advanced Pca** : Offer RP to highly selected patients with c T3b-T4N0 or any TN1 Pca only as part of multi-modal therapy (SR: strong)  
Perform an e-PLND in high-risk Pca (SR: Strong)  
Do not perform a frozen section of nodes during RP ....

## General Guidelines for Active Treatment of Pca: eau guidelines 2022



- ***Surgical treatment***
- Inform patients that no surgical approach (open, laparoscopic or **robotic** RP) has clearly shown superiority in terms of functional or onco results (SR: Weak)
- Perform an e-LND when a LND is deemed necessary (SR:Strong)
- Do not perform nerve sparing surgery when there is a risk of extracapsular extension (based on cT stage, ISUP grade, nomogram and mpMRI) (SR: Weak)



## Relative Contraindications for Robotic Radical Prostatectomy


- Patients with previous peritoneal or pelvic surgery.
- Prior benign prostatic hyperplasia (BPH) surgery
- Large prostate size, pose technical challenges and increase operative times and blood loss during robotic radical prostatectomy.
- Morbid obesity
- Patients with important co-morbidities .. pulmonary
- Patients with GLAUCOMA (??)

## Disadvantages of Robotic Techniques

- Economically, the robotic system is viable only for centers with a high volume of cases or multidisciplinary robotic use.
- The system cost exceeds \$ 2 million, and the annual maintenance costs range from \$150,000 to \$250,000
- The minimum number of procedures needed per year to cover the expenses is 150
- **This disadvantage will disappear with the new coming Systems (less expensive)**



From 4 arms Da Vinci R..... To



**20-22 SETTEMBRE 2023**

**BARI | VILLA ROMANAZZI CARDUCCI**

**7° Forum  
Mediterraneo  
2023 in Sanità®**

## **Hogo and Japanese R...and Single Port Robotic Surgery**

- **Not available in EUROPE**



.....Future: HUGO Robot





## HUGO Robot





## Hugo Robot: 3D Vision






### Da Vinci SP: Single Port (Chicago 2023)





**20-22 SETTEMBRE 2023**  
**BARI | VILLA ROMANAZZI CARDUCCI**


**7° Forum**  
**Mediterraneo**  
**2023 in Sanità®**





**20-22 SETTEMBRE 2023**  
**BARI | VILLA ROMANAZZI CARDUCCI**

**7° Forum**  
**Mediterraneo**  
**2023 in Sanità®**





**Grazie**



### **Delitti in materia di violazione del diritto d'autore (Art. 25-novies, D.Lgs. n. 231/2001) [articolo aggiunto dalla L. n. 99/2009]**

- Messa a disposizione del pubblico, in un sistema di reti telematiche, mediante connessioni di qualsiasi genere, di un'opera dell'ingegno protetta, o di parte di essa (art. 171, legge n.633/1941 comma 1 lett. a) bis)
- Reati di cui al punto precedente commessi su opere altrui non destinate alla pubblicazione qualora ne risulti offeso l'onore o la reputazione (art. 171, legge n.633/1941 comma 3)
- Abusiva duplicazione, per trarne profitto, di programmi per elaboratore; importazione, distribuzione, vendita o detenzione a scopo commerciale o imprenditoriale o concessione in locazione di programmi contenuti in supporti non contrassegnati dalla SIAE; predisposizione di mezzi per rimuovere o eludere i dispositivi di protezione di programmi per elaboratori (art. 171-bis legge n.633/1941 comma 1)
- Riproduzione, trasferimento su altro supporto, distribuzione, comunicazione, presentazione o dimostrazione in pubblico, del contenuto di una banca dati; estrazione o reimpiego della banca dati; distribuzione, vendita o concessione in locazione di banche di dati (art. 171-bis legge n.633/1941 comma 2)
- Abusiva duplicazione, riproduzione, trasmissione o diffusione in pubblico con qualsiasi procedimento, in tutto o in parte, di opere dell'ingegno destinate al circuito televisivo, cinematografico, della vendita o del noleggio di dischi, nastri o supporti analoghi o ogni altro supporto contenente fonogrammi o videogrammi di opere musicali, cinematografiche o audiovisive assimilate o sequenze di immagini in movimento; opere letterarie, drammatiche, scientifiche o didattiche, musicali o drammatico musicali, multimediali, anche se inserite in opere collettive o composite o banche dati; riproduzione, duplicazione, trasmissione o diffusione abusiva, vendita o commercio, cessione a qualsiasi titolo o importazione abusiva di oltre cinquanta copie o esemplari di opere tutelate dal diritto d'autore e da diritti connessi; immissione in un sistema di reti telematiche, mediante connessioni di qualsiasi genere, di un'opera dell'ingegno protetta dal diritto d'autore, o parte di essa (art. 171-ter legge n.633/1941)
- Mancata comunicazione alla SIAE dei dati di identificazione dei supporti non soggetti al contrassegno o falsa dichiarazione (art. 171-septies legge n.633/1941)
- Fraudolenta produzione, vendita, importazione, promozione, installazione, modifica, utilizzo per uso pubblico e privato di apparati o parti di apparati atti alla decodificazione di trasmissioni audiovisive ad accesso condizionato effettuate via etere, via satellite, via cavo, in forma sia analogica sia digitale (art. 171-octies legge n.633/1941).

**[Torna all'inizio](#)**